#United States #Plymouth Meeting #NCCN #cancer shortage #ifosfamide

Recent NCCN Survey Exposes Persistent Shortages in Cancer Medications

The urgency of addressing medication shortages in cancer treatment has taken center stage with the recent findings released by the National Comprehensive Cancer Network (NCCN). Notably, this is not a new crisis; NCCN began monitoring drug shortages over three years ago. The survey data, gathered from various pharmacy directors and clinical leaders in late August, reveals a startling statistic: 96% of the cancer centers surveyed report ongoing medication shortages, and every participating center, 100%, is facing a deficit of at least one essential anti-cancer drug.

Out of the centers surveyed, 94% are currently reporting a lack of ifosfamide, a chemotherapy agent crucial in treating several cancer types including bladder, testicular, and various leukemias and lymphomas. Meanwhile, 71% of the centers indicated shortages of carboplatin, a key component in many chemotherapy regimens, and 16% cited issues with cisplatin, another cornerstone medication.

The NCCN has been sounding the alarm over these shortages, which, despite their sustained focus, seem to remain prevalent and unchanged. According to Dr. Crystal S. Denlinger, CEO of NCCN, the persistence of these issues despite ongoing advocacy and alerts is indeed disheartening. She emphasizes that while cancer centers are innovating mitigation strategies to manage treatment plans amidst shortages, these efforts require significant resources that could otherwise enhance patient care and outcomes.

In a bid to maintain necessary treatment schedules, 61% of the respondents reported needing pharmacy-led strategies to tackle the medication shortages. Schools have implemented several approaches, including waste management and the exploration of alternative treatment plans, to ensure that patients receive proper care. However, these modifications come at a cost. A significant 90% of centers noted that altering treatment lines necessitated repeating prior authorization processes. This not only adds to the workload but also opens a potential window for delays in providing necessary treatments—an unacceptable risk for patients in need.

Interestingly, when survey respondents were asked if current policies at national or state levels have affected the situation, a mere 4% felt that the situation has improved, showcasing a critical consensus that changes have not translated into positive outcomes.

Furthermore, from a policy perspective, there is a clear call for economic incentives to foster high-quality manufacturing of generic cancer drugs. Many respondents believe that the economic landscape surrounding oncology generics is dire; they assert that without significant financial adjustments, shortages will likely continue. The desire for better information regarding generic suppliers and an earlier notification protocol from manufacturers to the FDA was also highlighted as a critical necessity to alleviate future disruptions.

The feedback from the survey leads to an urgent call to action. NCCN is part of the End Cancer Drug Shortages Coalition, which comprises numerous nonprofit organizations within hematology and oncology advocating for sustainable solutions to drug shortages. This coalition addressed the matter through a consensus statement earlier this year that outlines feasible policy recommendations aimed at resolving the crisis.

Amid these dire concerns, there's hope in that NCCN member institutions continue to collaborate and innovate within their frameworks to ensure they uphold the quality of patient care despite the prevailing challenges. The organization urges policymakers, manufacturers, and stakeholders in the pharmaceutical ecosystem to collaborate for sustainable solutions that address not just the symptoms of these shortages but also the root causes.

For anyone intrigued by the survey’s detailed findings, NCCN has published the results and additional insights on their website at NCCN.org/drug-shortages. As the landscape of cancer care steadily evolves, it remains essential that concerted efforts are in place to maneuver through these formidable hurdles.

• ---

About NCCN

The National Comprehensive Cancer Network (NCCN) is a nonprofit alliance committed to advancing quality cancer care and reducing disparities in access to treatment. Through their clinical practice guidelines, advocate initiatives, and educational programs, NCCN aims to enhance outcomes and quality of life for cancer patients nationwide. For more information, visit NCCN.org.